These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike. Changrob S; Fu Y; Guthmiller JJ; Halfmann PJ; Li L; Stamper CT; Dugan HL; Accola M; Rehrauer W; Zheng NY; Huang M; Wang J; Erickson SA; Utset HA; Graves HM; Amanat F; Sather DN; Krammer F; Kawaoka Y; Wilson PC mBio; 2021 Dec; 12(6):e0297521. PubMed ID: 34781736 [TBL] [Abstract][Full Text] [Related]
24. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection. Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290 [TBL] [Abstract][Full Text] [Related]
25. Generation of neutralizing antibodies against Omicron, Gamma and Delta SARS-CoV-2 variants following CoronaVac vaccination. Silva ARD; Villas-Boas LS; Tozetto-Mendoza TR; Honorato L; Paula A; Witkin SS; Mendes-Correa MC Rev Inst Med Trop Sao Paulo; 2022; 64():e19. PubMed ID: 35239863 [TBL] [Abstract][Full Text] [Related]
26. Antibody Cocktail Exhibits Broad Neutralization Activity Against SARS-CoV-2 and SARS-CoV-2 Variants. Qu Y; Zhang X; Wang M; Sun L; Jiang Y; Li C; Wu W; Chen Z; Yin Q; Jiang X; Liu Y; Li C; Li J; Ying T; Li D; Zhan F; Wang Y; Guan W; Wang S; Liang M Virol Sin; 2021 Oct; 36(5):934-947. PubMed ID: 34224110 [TBL] [Abstract][Full Text] [Related]
27. Safety, Virologic Efficacy, and Pharmacokinetics of CT-P59, a Neutralizing Monoclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Protein: Two Randomized, Placebo-Controlled, Phase I Studies in Healthy Individuals and Patients With Mild SARS-CoV-2 Infection. Kim JY; Jang YR; Hong JH; Jung JG; Park JH; Streinu-Cercel A; Streinu-Cercel A; Săndulescu O; Lee SJ; Kim SH; Jung NH; Lee SG; Park JE; Kim MK; Jeon DB; Lee YJ; Kim BS; Lee YM; Kim YS Clin Ther; 2021 Oct; 43(10):1706-1727. PubMed ID: 34551869 [TBL] [Abstract][Full Text] [Related]
28. Identification and Analysis of Monoclonal Antibodies with Neutralizing Activity against Diverse SARS-CoV-2 Variants. Ishimaru H; Nishimura M; Tjan LH; Sutandhio S; Marini MI; Effendi GB; Shigematsu H; Kato K; Hasegawa N; Aoki K; Kurahashi Y; Furukawa K; Shinohara M; Nakamura T; Arii J; Nagano T; Nakamura S; Sano S; Iwata S; Okamura S; Mori Y J Virol; 2023 Jun; 97(6):e0028623. PubMed ID: 37191569 [TBL] [Abstract][Full Text] [Related]
29. A nasal omicron vaccine booster elicits potent neutralizing antibody response against emerging SARS-CoV-2 variants. Lam JY; Ng YY; Yuen CK; Wong WM; Yuen KY; Kok KH Emerg Microbes Infect; 2022 Dec; 11(1):964-967. PubMed ID: 35275039 [TBL] [Abstract][Full Text] [Related]
30. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Yang S; Li Y; Dai L; Wang J; He P; Li C; Fang X; Wang C; Zhao X; Huang E; Wu C; Zhong Z; Wang F; Duan X; Tian S; Wu L; Liu Y; Luo Y; Chen Z; Li F; Li J; Yu X; Ren H; Liu L; Meng S; Yan J; Hu Z; Gao L; Gao GF Lancet Infect Dis; 2021 Aug; 21(8):1107-1119. PubMed ID: 33773111 [TBL] [Abstract][Full Text] [Related]
31. A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern. Yuan M; Chen X; Zhu Y; Dong X; Liu Y; Qian Z; Ye L; Liu P J Virol; 2022 Aug; 96(16):e0077522. PubMed ID: 35916510 [TBL] [Abstract][Full Text] [Related]
32. Real-world effectiveness of an intranasal spray A8G6 antibody cocktail in the post-exposure prophylaxis of COVID-19. Li X; Peng P; Deng H; Yang Q; Chen S; Li B; He M; Jin A; Yang Z; Tang N; Huang A Signal Transduct Target Ther; 2023 Oct; 8(1):403. PubMed ID: 37867182 [TBL] [Abstract][Full Text] [Related]
33. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial. Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543 [TBL] [Abstract][Full Text] [Related]
34. Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b trial. Wu JD; Li JX; Liu J; Wang HM; Zhou GH; Li J; Wu D; Chen X; Feng Y; Qi XY; Wang X; Gou JB; Ma TL; Yang XY; Xu LF; Wan P; Zhu T; Wang ZF; Zhu FC; Lancet Infect Dis; 2023 Sep; 23(9):1020-1030. PubMed ID: 37216958 [TBL] [Abstract][Full Text] [Related]
35. A Booster Dose of CoronaVac Increases Neutralizing Antibodies and T Cells that Recognize Delta and Omicron Variants of Concern. Schultz BM; Melo-González F; Duarte LF; Gálvez NMS; Pacheco GA; Soto JA; Berríos-Rojas RV; González LA; Moreno-Tapia D; Rivera-Pérez D; Ríos M; Vázquez Y; Hoppe-Elsholz G; Andrade-Parra CA; Vallejos OP; Piña-Iturbe A; Iturriaga C; Urzua M; Navarrete MS; Rojas Á; Fasce R; Fernández J; Mora J; Ramírez E; Gaete-Argel A; Acevedo ML; Valiente-Echeverría F; Soto-Rifo R; Weiskopf D; Grifoni A; Sette A; Zeng G; Meng W; ; González-Aramundiz JV; González PA; Abarca K; Kalergis AM; Bueno SM mBio; 2022 Aug; 13(4):e0142322. PubMed ID: 35946814 [TBL] [Abstract][Full Text] [Related]
37. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Zhu FC; Guan XH; Li YH; Huang JY; Jiang T; Hou LH; Li JX; Yang BF; Wang L; Wang WJ; Wu SP; Wang Z; Wu XH; Xu JJ; Zhang Z; Jia SY; Wang BS; Hu Y; Liu JJ; Zhang J; Qian XA; Li Q; Pan HX; Jiang HD; Deng P; Gou JB; Wang XW; Wang XH; Chen W Lancet; 2020 Aug; 396(10249):479-488. PubMed ID: 32702299 [TBL] [Abstract][Full Text] [Related]
38. Broad strategies for neutralizing SARS-CoV-2 and other human coronaviruses with monoclonal antibodies. Ling Z; Yi C; Sun X; Yang Z; Sun B Sci China Life Sci; 2023 Apr; 66(4):658-678. PubMed ID: 36443513 [TBL] [Abstract][Full Text] [Related]
39. Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials. Zeng G; Wu Q; Pan H; Li M; Yang J; Wang L; Wu Z; Jiang D; Deng X; Chu K; Zheng W; Wang L; Lu W; Han B; Zhao Y; Zhu F; Yu H; Yin W Lancet Infect Dis; 2022 Apr; 22(4):483-495. PubMed ID: 34890537 [TBL] [Abstract][Full Text] [Related]
40. Structural Study of SARS-CoV-2 Antibodies Identifies a Broad-Spectrum Antibody That Neutralizes the Omicron Variant by Disassembling the Spike Trimer. Zhan W; Tian X; Zhang X; Xing S; Song W; Liu Q; Hao A; Hu Y; Zhang M; Ying T; Chen Z; Lan F; Sun L J Virol; 2022 Aug; 96(16):e0048022. PubMed ID: 35924918 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]